Diagnostic Biochips introduced a neural probe platform designed to record functional electrophysiology from brain organoids at scale, a capability the company says will improve early‑stage predictive validity and reduce late‑stage clinical failures. Company lead Brian Jamieson described an approach that integrates high‑resolution electrical readouts with organoid cultures to capture neural circuit activity rather than relying solely on molecular markers. The technology targets drug discovery teams seeking physiologic functional endpoints in vitro; by detecting electrophysiological signatures of efficacy and toxicity, the probe could triage candidates earlier in development and inform translational risk assessment. Diagnostic Biochips emphasized compatibility with existing organoid workflows and potential to shorten lead selection timelines.